Georgia Niki Kamboj, MBBS, PhD

Georgia Kamboj practices at West Coast Retina in San Francisco, California.

Georgia Kamboj's NPI, 1366946170, was assigned on March 19, 2018. Georgia Kamboj graduated from The Flinders University of South Australia School of Medicine in 2011. Georgia Kamboj holds California license A168668.

Georgia Kamboj's primary practice is West Coast Retina, at 1445 Bush St, San Francisco, CA 94109-5520. The practice phone is (415) 972-4600.

Georgia Kamboj's primary practice is West Coast Retina in San Francisco, California. Georgia Kamboj is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is Alameda Health System. Dmand AI also links Georgia Kamboj to 3 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Georgia Kamboj practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Georgia Kamboj's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Georgia Kamboj is board certified in ophthalmology by the American Board of Ophthalmology. Georgia Kamboj is licensed in California.

Dmand AI lists age-related macular degeneration, hypertensive retinopathy, retinal occlusion, surgical retina and vitreous procedures, vision problems and visual impairment and blindness among the conditions Georgia Kamboj treats.

CMS data shows 3,201 Medicare services from Georgia Kamboj across 9 procedure codes in 2024, for 256 Medicare patients. Medicare paid $204,798 for them. Every service was in an office.

CMS counts 256 Medicare patients who saw Georgia Kamboj in 2024. The largest group is 75 to 84, with 90 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Georgia Kamboj's median patient age at 66, with 43% women.

In 2024, Georgia Kamboj wrote 98 Medicare Part D claims for 43 patients. 59% of them were for generic drugs. CMS names the drug for 34 of them, across 2 drugs with 11 or more claims each, at $894 in total drug cost. In 2023, CMS named 40 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Georgia Kamboj for performance year 2024, reported as part of a group. Georgia Kamboj accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Georgia Kamboj in 2023. Georgia Kamboj's most frequent co-authors are Theodore Leng, MD and Creed Michael Stary, MD, PhD.

CMS Open Payments shows 26 general payments to Georgia Kamboj from 8 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $410. It also lists 8 research payments totaling $1,438 in 2025, naming 1 clinical trial.

Georgia Kamboj graduated from The Flinders University of South Australia School of Medicine in 2011.

Georgia Kamboj is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.